| __timestamp | Supernus Pharmaceuticals, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 5758000 | 179279000 |
| Thursday, January 1, 2015 | 8423000 | 186359000 |
| Friday, January 1, 2016 | 11986000 | 171785000 |
| Sunday, January 1, 2017 | 15215000 | 208136000 |
| Monday, January 1, 2018 | 15356000 | 198405000 |
| Tuesday, January 1, 2019 | 16660000 | 224169000 |
| Wednesday, January 1, 2020 | 52459000 | 245044000 |
| Friday, January 1, 2021 | 75061000 | 252314000 |
| Saturday, January 1, 2022 | 87221000 | 268225000 |
| Sunday, January 1, 2023 | 83779000 | 304629000 |
| Monday, January 1, 2024 | 324203000 |
Unveiling the hidden dimensions of data
In the competitive landscape of pharmaceuticals, cost efficiency is a critical metric. This analysis compares the cost of revenue for Supernus Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd. from 2014 to 2023. Over this period, Taro consistently outpaced Supernus, with its cost of revenue averaging around 233% higher. Notably, Taro's cost of revenue peaked in 2023, reaching approximately 304 million, a 70% increase from 2014. Meanwhile, Supernus saw a significant rise in 2020, with costs surging by 215% compared to 2014, reflecting strategic shifts or market dynamics. However, data for Supernus in 2024 is missing, leaving room for speculation on its future trajectory. This comparison highlights the varying strategies and market positions of these two industry players, offering insights into their operational efficiencies and financial health.
Eli Lilly and Company vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Zoetis Inc. and Taro Pharmaceutical Industries Ltd.
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.
Cost of Revenue Trends: Dr. Reddy's Laboratories Limited vs Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: Catalent, Inc. and Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: Jazz Pharmaceuticals plc and Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Lantheus Holdings, Inc. and Supernus Pharmaceuticals, Inc.'s Expenses
Amneal Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: HUTCHMED (China) Limited and Taro Pharmaceutical Industries Ltd.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Mesoblast Limited and Taro Pharmaceutical Industries Ltd.
Cost of Revenue Trends: Taro Pharmaceutical Industries Ltd. vs Evotec SE